CD10 is expressed in the stroma of malignant ovarian carcinomas, but not in benign adenomas or in normal ovaries, and its expression inversely correlates with histologic tumour grade . In ovarian carcinoma, ET-1 promotes cell growth, invasion and angiogenesis by acting as an autocrine/paracrine growth factor (Bagnato et al., 1999; Salani et al., 2000) . CD10 may directly influence the local concentration of ET-1 via its enzymatic activity thus contrasting the mitogenic effects of ET-1, suggesting that CD10 plays a role in the biology of neoplastic transformation or in the control of ovarian cancer progression . It has been suggested that CD10 may function as a tumour suppressor factor in ovarian cancer progression, as well as in lung and prostate cancer (Papandreou et al., 1998) . In addition to its role in the control of ovarian carcinoma progression, Kajiyama et al. demonstrated that CD10 enhances susceptibility to paclitaxel in the SKOV3 ovarian carcinoma cell line, resulting in increased apoptosis and reduced tumour formation and invasiveness in in vivo models. This evidence suggests that CD10 might serve as a potential target for gene therapy in metastatic ovarian carcinoma. However, no experimental data in this regard is so far available, and this aspect deserves further investigation.
CD13
3.1 Structure and expression Human CD13 was isolated in 1963 from pig kidney (Pfleiderer et al., 1963) and is a transmembrane protein also known as aminopeptidase N (APN), alanine aminopeptidase, microsomal aminopeptidase, amino oligopeptidase, GP150. CD13 cleaves N-terminal neutral amino acids of a number of peptides and proteins. The CD13 gene is located on the long arm of chromosome 15 and the coding sequence spans 20 exons (Lerche et al., 1996) . CD13 consists of 967 amino acids constituting a short N-terminal cytoplasmic domain, a single transmembrane fragment and a large ectodomain encompassing the active site (Olsen et al., 1988) . The CD13 protein is predominantly expressed in stem cells and cells of the granulocytic and monocytic lineages at discrete stages of differentiation (Razak et al., 1992) . Nonhematopoietic cells, such as renal proximal tubular epithelial cells, small intestinal epithelium, biliary canaliculae, bone marrow stromal cells, fibroblasts and osteoclasts are also CD13-positive (Metzgar et al., 1981; Noren, 1986) . Deregulated expression of membrane and/or soluble forms of CD13 has been observed in many diseases. For example, CD13 is overexpressed in acute and chronic myeloid leukaemias (Antczak et al., 2001) and in anaplastic large cell lymphomas (Dunphy et al., 2000) . High expression of CD13 has been detected in various solid tumours such as melanoma (Fujii et al., 1995) , renal (Kitamura et al., 1990) , pancreas (Ikeda et al., 2003) , colon (Hashida et al., 2002) , prostate (Ishii et al., 2001a) , gastric (Carl-McGrath et al., 2004) , thyroid (Kehlen et al., 2003) and ovarian cancers (Yamashita et al., 2007) . In ovarian cancer CD13 expression is associated with the histological subtype: over 80% of serous and mucinous carcinomas but only 20% of clear cell carcinomas are CD13-positive (van Hensbergen et al., 2004) . Moreover, CD13 also exists as a soluble form, likely originating from shedding of the membrane protein, which has a potent enzymatic activity in the plasma and reactive effusions of cancer patients, such as ascites from ovarian cancer patients (van Hensbergen et al., 2002) .
Functions
CD13 is a multifunctional protein acting as an enzyme, a receptor and a signalling molecule. As an enzyme, CD13 regulates the activity of numerous peptides involved in important biological processes by removing their N-terminal aminoacids, mainly neutral aminoacids (Noren, 1986) . CD13 hydrolyses the N-terminal Arg of angiotensin III to generate angiotensin IV (Danziger, 2008) and participates in the metabolism of glutathione, somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin FQ and peptides derived from the thrombin receptor (Noble et al., 1997) . In the intestinal brush border, the CD13 enzymatic domain faces the lumen and has been supposed to play an important role in the final stages of the digestion of small peptides (Semenza, 1986) . CD13 has been postulated to cooperate with CD10 in the hydrolysis of oligopeptides in the small intestine (Semenza, 1986) , and to inactivate opioid peptides and enkephalins in the brain (Matsas et al., 1985) and the chemotactic peptide Met-Leu-Phe during neutrophil-mediated inflammatory responses (Connelly et al., 1985) .
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Ectoenzymes in Epithelial Ovarian Carcinoma: Potential Diagnostic Markers and Therapeutic Targets 249 CD13 also acts as a receptor for coronaviruses, which exploit the endocytosis of the molecule to enter into respiratory and intestinal epithelial cells (Nomura et al., 2004) . Moreover, CD13 is involved in transduction of intracellular signals, converging on mitogen-activated protein kinases, such as ERK1/2, JNK, and p38, in association with auxiliary proteins such as galectin-3 (Santos et al., 2000) , galectin-4 (Danielsen et al., 1997) , RECK (Miki et al., 2007) and the tumour-associated antigen L6 (Chang et al., 2005) . CD13 activates or inactivates bioactive peptides on the cell surface, thus regulating their activities on adjacent cells. CD13 has a wide range of functions, including a role in antigen presentation by processing antigenic peptides protruding from MHC class II molecules (Larsen et al., 1996) , in phagocytosis (Mina-Osorio et al., 2005) , in lymphocyte and monocyte adhesion and aggregation (Mina-Osorio et al., 2006) and intracellular signal transduction (Santos, et al., 2000) , in stem cell differentiation (Chen et al., 2007) , cholesterol uptake (Knopfel et al., 2007) and spermatozoid motility (Carlsson et al., 2006) . Several studies have confirmed a correlation between CD13 expression and increased malignant behaviour in melanoma (Carlsson, et al., 2006) , prostate (Ishii, et al., 2001a) , colon (Hashida, et al., 2002) and lung cancers (Chang, et al., 2005) . In these tumours it is implicated in cell motility and in the degradation of and invasion through the extracellular matrix (ECM) (Saiki et al., 1993) . By contrast, an inverse correlation has been reported between CD13 expression and tumour progression in renal cancer (Ishii et al., 2001b) . Several studies have demonstrated that CD13 expression is induced in tumour microvascular endothelial cell by angiogenic cytokines and hypoxia and that it regulates endothelial cell tube formation both in in vitro (Hashida, et al., 2002) and in in vivo models (Bhagwat et al., 2001) . Functional studies indicate that CD13 expression is associated with a long spindle fibroblastlike morphology and a migratory phenotype accompanied by enhanced secretion of MMP-2 in various ovarian cancer cell lines . Since CD13 is involved in cell motility, in the invasive potential of tumour cells and in the neoangiogenic processes, it holds promise as a therapeutic tumour target. In ovarian cancer it has been demonstrated that suppression of CD13 activity by specific inhibitors (including blocking antibodies, bestatin or actinonin) reduces the proliferative, migratory and angiogenic potential of tumour cells, as well as the peritoneal dissemination in vivo in mouse models, leading to prolonged survival . It has also been determined that CD13 is involved in the chemosensivity and radiosensitivity of ovarian cancer cells. Indeed, combined treatment of tumour cells with bestatin and paclitaxel showed a significant increase in apoptosis and an improved outcome of ovarian cancer patients (Yamashita, et al., 2007) . Taken together, the results from these studies suggest that inhibition of CD13 enzymatic activity may provide a new approach for improving the efficacy of ovarian carcinoma therapy, leading to reduced cell proliferation, motility, invasiveness, angiogenesis and chemoresistance of ovarian cancer cells.
CD26
4.1 Structure and expression CD26, also known as dipeptidyl peptidase IV (DPPIV), adenosine deaminase binding protein (ADAbp) or EC 3.4.14.5, is a multifunctional type II cell surface glycoprotein. CD26 is a 110 kDa aminopeptidase that is catalytically active only as a dimer. Each monomer consists of two domains, an / -hydrolase domain (residues 39-51 and 501-766) and an www.intechopen.com
Ovarian Cancer -Basic Science Perspective 250 eight-blade -propeller domain (residues 59-497), that enclose a large cavity of ~ 30-45A° in diameter. Access to this cavity is provided by a large side opening of ~15A° (Aertgeerts et al., 2004) . However, only elongated peptides, or unfolded or partly unfolded protein fragments, can reach the small pocket within this cavity that contains the active site. The main enzymatic activity of CD26 is a serine protease activity with a post-proline dipeptidyl aminopeptidase activity, preferentially cleaving Xaa-Pro or Xaa-Ala dipeptides (where Xaa is any amino acid except Pro) from the N-terminus of polypeptides. CD26 contains nine potential N-linked glycosylation sites that lie predominantly on the propeller domain, near the dimerization interface (Engel et al., 2003) . The human CD26 gene consists of 26 exons and is located on the long arm of chromosome 2 (Tanaka et al., 1992) .
Functions
CD26 exerts pivotal roles in nutrition, metabolism, immune and endocrine systems, bone marrow mobilization, cancer growth and cell adhesion. CD26 activates or deactivates various bioactive peptides on the cell surface or in the extracellular environment, by cleaving them enzymatically, therefore regulating their availability for adjacent cells. CD26 substrates include cytokines and several chemokines: substance P, chorionic gonadotropin, tumour necrosis factor (TNF-), interleukin-2, stromal cell-derived factor 1a, RANTES, neuropeptide Y, peptide YY, glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic peptide (Gorrell, 2005) . Besides its enzymatic activity, CD26 shows a variety of functions, including regulation of inflammatory and immunological responses, signal transduction, interactions with extracellular matrix proteins and apoptosis. CD26 ligands include adenosine deaminase (ADA) (Morrison et al., 1993 ), kidney Na + /H + ion exchanger 3 (Girardi et al., 2001 ) and fibronectin (Cheng et al., 2003) . CD26 has been consistently associated with cancer since its identification (ten Kate et al., 1984) . A number of recent studies have provided evidence that CD26 plays a role in discrete steps of tumour progression, such as cell adhesion, invasion and cell cycle arrest (Pethiyagoda et al., 2000) . In selected carcinoma tissues, CD26 is misexpressed and it can function either as an oncogene or as a tumour suppressor gene. Its expression is upregulated and associated with tumour aggressiveness in T and B lymphomas and leukaemias (Bauvois et al., 1999; Carbone et al., 1995; Dang et al., 2003) , thyroid follicular tumours (de Micco et al., 2008) , papillary carcinomas, astrocytic tumours (Stremenova et al., 2007) and gastrointestinal stromal tumours (Yamaguchi et al., 2008) . Conversely, loss of CD26 occurs during malignant transformation of melanocytes into melanoma (Wesley et al., 1999) , indicating a possible role of the molecule in suppressing the malignant transformation of melanocytes. The precise biological mechanism through which CD26 regulates tumour cell progression remains controversial. According to Wesley et al., high CD26 expression leads to a loss of tumorigenicity through its serine protease activity (Wesley, et al., 1999) . On the other hand, the suppressive effect of CD26 on melanoma's malignant phenotype is related neither to the protease activity located at the extracellular domain nor to the signal transduction related to the cytoplasmic domain (Pethiyagoda et al., 2000) . In 2002 Kajiyama et al. first described the expression of CD26 in ovarian carcinoma cell lines and tissues. CD26 immunoreactivity was observed on surgically resected ovarian carcinoma of different histotypes, but was not found in stromal cells. CD26 expression in ovarian cancer cell lines is associated with an epithelioid morphology. Indeed, forced expression of CD26 in an ovarian cancer cell line results in marked morphological changes from a fibroblastic/spindle-shaped appearance toward an epithelioid pattern, which is paralleled by the shift from mesenchymal to epithelial markers (Kajiyama et al., 2002) . Exogenous expression of CD26 leads to a significant reduction in the invasive potential in ovarian carcinoma cell lines in vitro and an increased E-cadherin expression. Indeed, CD26 expression in ovarian cancer cell lines positively correlates with E-cadherin expression and induces the upregulation of both E-cadherin and -catenin, which play a key role in the suppression of invasive and metastatic phenotype of cancer cells . Moreover, in ovarian carcinoma cell lines CD26 expression negatively correlates with MMP-2 expression, and the expression levels of both MMP-2 and MT1-MMP are significantly reduced in CD26-transfected cells. Overexpression of CD26 also increases expression levels of TIMP-1 and TIMP-2, known to be key inhibitors of tumour invasion, angiogenesis and metastasis (Kikkawa et al., 2005) . Overexpression of CD26 reduced intraperitoneal dissemination of carcinoma cells and prolonged survival time in vivo in a mouse orthotopic model. Ovarian carcinoma cell lines with higher CD26 expression has significantly less metastatic potential when injected into the abdominal cavity of nude mice than the CD26-negative control cells (Mizutani et al., 2003) . Consistent with this, the intensity of CD26 immunohistochemical staining in tissues proved to be stronger in well-differentiated and non-infiltrating ovarian carcinomas, thus indicating that the decrease of CD26 is related to neoplastic transformation and tumour progression (Zhang et al., 2008) . A positive correlation between CD26 expression and sensitivity to paclitaxel has been described in several ovarian carcinoma cell lines. Forced expression of CD26 in a CD26-negative ovarian cancer cell line significantly enhanced sensitivity to paclitaxel by increasing the rate of apoptotic cells through the repression of the transcriptional factor Twist, a master regulator of epithelial-mesenchymal transition, linked to paclitaxel resistance. These data were corroborated by the observation that paclitaxel-resistant NOS-PR cells showed reduced expression of CD26. However, no significant alteration in paclitaxel sensitivity was observed in the presence of a specific inhibitor of DPPIV activity in CD26-transfected or natively CD26-overexpressing cells (Kajiyama et al., 2010) . Further understanding of the anti-invasive effect of CD26 may prove useful in devising new strategies in the control of ovarian cancer and other carcinomas. Like other membranebound peptidases, CD26 may soon be destined for use not only as a new diagnostic/prognostic marker, but also as a molecular target in novel therapeutic strategies.
CD73
5.1 Structure and expression CD73, also known as ecto-5′-nucleotidase (ecto-5′-NT), is a glycosylphosphatidylinositol (GPI)-anchored ectoenzyme composed of two identical subunits of 70-74 kDa. The mature protein consists of 548 amino acids and corresponds to a molecular mass of ~63 kDa (Airas et al., 1993) . The human CD73 gene has been mapped to region q14-q21 of chromosome 6. CD73 is abundantly expressed by vascular endothelial cells (Jalkanen et al., 2008) and by a subpopulation of peripheral blood lymphocytes represented by regulatory T cells and primed uncommitted CD4-positive T cells. Follicular dendritic cells (Airas, 1998) , intestinal epithelial cells (Strohmeier et al., 1997) , fibroblasts (Nemoto et al., 2004) (Maienschein et al., 1996) and mesenchymal stem cells (Barry et al., 2001 ) have been reported to express CD73.
Functions
It has been proposed that CD73 behaves as an adhesion molecule modulating lymphocyteendothelial cell interactions (Airas et al., 2000) . Furthermore, CD73 is known to play a critical role in vivo in maintaining the integrity of the vascular endothelium during hypoxia (Colgan et al., 2006) , in mediating efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis and in regulating leukocyteendothelium interaction during cardiac ischemia-reperfusion (Koszalka et al., 2004) . CD73 catalyzes the dephosphorylation of purine and pyrimidine ribo-and deoxyribonucleoside monophosphates to the corresponding nucleoside. This ectoenzymatic cascade operates in tandem with CD39 (ecto-ATPase) and catalyzes the conversion of AMP to bioactive adenosine from adenosine triphosphate (ATP) which is often released into the extracellular environment from damaged or inflamed target cells (Stagg et al., 2010b) . Extracellular adenosine induces potent immunosuppressive effects, mainly mediated through four adenosine-binding G protein-coupled receptors. In addition to its enzymatic function, CD73 has been suggested to have a role in T cell signalling (Resta et al., 1998) . The resistance of many solid tumours to host immune responses has been largely attributed to a spectrum of tumour-associated immune-suppressive mechanisms. During tumour progression, tumour cells promote a tolerant microenvironment and activation of multiple immunosuppressive mechanisms, which may act in concert to attenuate an effective immune responses (Rabinovich et al., 2007) . It is thought that tipping the balance from an immune-suppressive to an immune-active environment is necessary for effective cancer immunotherapy (Rabinovich et al., 2007) . Adenosine is a purine nucleoside reaching high concentrations within solid tumours (Ohta et al., 2006) where it promotes tumour growth through the stimulation of tumour angiogenesis (Stagg & Smyth, 2010b ) and inhibition of anti-tumour immune responses (Hoskin et al., 2008) . However, the mechanisms whereby adenosine accumulates in solid tumours and the effects resulting from this accumulation are not completely understood. CD73 expression has been reported in several tumour types (Stagg & Smyth, 2010b) , including ovarian cancer (Jin et al., 2010) and its expression has been associated with a prometastatic phenotype in melanoma and breast cancer (Leth-Larsen et al., 2009) . Although in vitro studies suggested that CD73 expression can enhance breast cancer cell migration and invasion, the underlying mechanisms remain elusive. In breast cancer cells, CD73 expression significantly inhibits endogenous adaptive anti-tumour immunosurveillance, in addition, CD73-derived adenosine enhances tumour cell migration in vitro and metastasis in vivo through the activation of A2B adenosine receptors (Stagg et al., 2010a) . CD73 expression has been shown to be regulated by estrogen receptors, whereby loss of estrogen receptors significantly enhances CD73 expression (Spychala et al., 2004) . CD73 is highly expressed in many human solid tumours (Salmi et al., 2011) , and its high expression and activity are associated with tumour invasiveness and metastasis (Stagg et al., 2010a) and with shorter patient survival. Recently it has been demonstrated that exosomes released by cancer cells in vitro and in biological effusions are able to dephosphorylate exogenous ATP and 5′AMP to form adenosine. These hydrolytic activities have been in part attributed to expression of functional CD39 and CD73 by exosomes. This mechanism may contribute to augmenting www.intechopen.com Ectoenzymes in Epithelial Ovarian Carcinoma: Potential Diagnostic Markers and Therapeutic Targets 253 adenosine levels within the tumour microenvironment and hence participate to the negative regulation of T cell function (Clayton et al., 2011) . CD73 expressed in ovarian cancer negatively modulates tumour antigen-specific T cell immunity. Indeed, it has been demonstrated that knockdown of CD73 on tumour cells by siRNA improved anti-tumour T cell responses, completely restoring the efficacy of adoptive T cell therapy and leading to long-term tumour-free survival in tumour-bearing mice. Moreover, in a mouse model, host CD73 deficiency decreased the ovarian carcinoma burden and increased mouse survival in a T cell-dependent manner. Accordingly, reduction of both tumour and host CD73 resulted in an optimal anti-tumour effect (Jin et al., 2010) . Pharmacological blockade of CD73 using the specific inhibitor , -methylene adenosine 5′-diphosphate (APCP) or a blocking anti-CD73 monoclonal antibody inhibited tumour growth and promoted efficacy of adoptive T cell therapy (Zhang, 2010) , suggesting that CD73-targeted therapy might be a promising and rational approach to cancer treatment (Häusler SF et al., 2011) . In summary, detailed analysis of CD73 expression on tumour cells and/or host cells regulating anti-tumour immunity may have important consequences on our understanding of immunosuppressive mechanisms in the tumour microenvironment that support tumour evasion. Inhibition of CD73 could be a therapeutic adjuvant to improve cancer immunotherapy.
CD157
6.1 Structure and expression CD157/BST-1 is a GPI-anchored glycoprotein encoded by a member of a gene family of NADase/ADP-ribosyl cyclase, which includes CD38. The CD38 and bone marrow stromal cell antigen 1 (BST-1) genes arose by gene duplication before the divergence of humans and rodents (Ferrero et al., 1997) . The human CD157 gene is located on chromosome 4p15, it spans ~35 kb and consists of nine exons (Muraoka et al., 1996) . Although CD157 was initially characterised as a stromal (Kaisho et al., 1994) and myeloid surface antigen (Goldstein et al., 1993) , it is also expressed by certain other cell types that include vascular endothelial cells (Ortolan et al., 2002) and mesothelial cells (Ross et al., 1998) .
Functions
CD157 is an ectoenzyme that cleave extracellular nicotinamide adenine dinucleotide (NAD) and NADP+, generating cyclic ADP ribose (cADPR), NAADP+, and ADPR. Beside their role as mediators of intracellular calcium release (Galione, 1994) , the products of CD157-operated NAD cleavage can act as extracellular immunomodifiers (Haag et al., 2007) . Emerging data indicated that these metabolites can act extracellularly as paracrine factors (Moreschi et al., 2008) . Moreover, the catalytic reactions generate substrate for ADP-ribosyl transferases and polymerases involved in cell signalling, DNA repair and apoptosis (Haag et al., 2007) . In addition, CD157 possesses receptor activity, indeed, it interacts with other surface molecules thus acquiring the ability to transduce signals (Malavasi et al., 2008) . Accumulating evidence indicates that CD157 is a key molecule in the control of leukocyte adhesion, migration and diapedesis (Funaro, 2004; Ortolan, 2006) . CD157 establishes a structural interaction with 1 and 2 integrins (Lavagno et al., 2007) and, following antibody-induced cross-linking, promotes their relocation into detergentresistant membrane domains, thus driving the dynamic reorganization of signalling-competent membrane microdomains. Moreover, CD157 effectively contributes to the integrin-driven signalling network that is critical during leukocyte transmigration (Lo Buono et al., 2011) . Recently, we demonstrated that CD157 is expressed in epithelial ovarian cancer (EOC) primary cell cultures and tissues, and it is involved in interactions among EOC cells, extracellular matrix proteins, and mesothelial cells which ultimately control tumour cell migration and invasion. The results inferred in vitro were validated by clinical evidence: CD157 was expressed by 93% of EOC analysed and high CD157 expression was associated with rapid tumour relapse in patients. Moreover, CD157 appears to be a marker of poor prognosis in the serous subtype of ovarian cancer, which is the most frequent and aggressive type. Multivariate survival analysis showed that CD157 is an independent prognostic factor of tumour relapse shortly after surgical debulking of ovarian cancer (Ortolan et al., 2010) . Several lines of evidence point to the fact that high levels of CD157 are associated with more aggressive ovarian cancer. First, forced expression of CD157 in CD157-negative NIH:OVCAR-3 cells substantially increased cell motility, a prerequisite for dissemination. Second, blockade of CD157 activity, either by a specific monoclonal antibody in vitro or by its weak expression in patients, was associated with reduced invasion and migration by tumour cells. Finally, clinical observations revealed that high CD157 correlated with rapid tumour relapse (Ortolan et al., 2010) . However, how CD157 might contribute to a more aggressive ovarian cancer remains to be defined (Annunziata et al., 2010) . Our results support the rationale for the future use of CD157 as a potential diagnostic target for EOC, providing the opportunity to develop new strategies using CD157 as a therapeutic target to prevent tumour dissemination in patients with serous ovarian cancer.
Autotaxin/CD203c
7.1 Structure and expression Autotaxin (ATX) also known as CD203c or ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2), is a cell motility-stimulating factor originally isolated from human melanoma cells (Stracke et al., 1992) . It is a member of the ENPP protein family, which includes membrane-associated or secreted ectoenzymes that hydrolyze pyrophosphate or phosphodiester bonds in various extracellular compounds, such as nucleotides and lysophospholipids (Tokumura et al., 2002) . ATX/CD203c is a soluble 125 kDa glycoprotein encoded by a single gene located on human chromosome 8. Three alternatively spliced isoforms have been reported: , and . Isoform , considered the canonical form, is the predominant one, and is expressed in peripheral tissues while isoform is more highly expressed in the central nervous system. Both and variants are catalytically active, whereas the isoform is rapidly degraded into smaller inactive forms (Giganti et al., 2008) . Autotaxin contains a catalytic domain, which is responsible for enzymatic activity and two additional domains, a somatomedin-B-like domain and a nuclease-like domain, which are located at the N-terminus and C-terminus of the protein, respectively. The somatomedin-B-like domain is rich in cysteine residues and contains an RGD tripeptide motif that is possibly involved in cell-extracellular matrix interactions. The nuclease-like domain contains an EF hand-like motif, structurally similar to the DNA-or RNA-non-specific endonucleases but it is catalytically inactive. All three domains are required for the catalytic activity (Nishimasu et al., 2011) .
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ATX is predominantly expressed in brain, kidney, placenta, ovary, small intestine and in body fluids such as plasma (Tokumura et al., 2002) , cerebral spinal fluid, saliva, and follicular and amniotic fluids (Giganti et al., 2008; Nishimasu et al., 2011) .
Functions
Autotaxin is defined as a multi-functional protein producing (i) lysophosphatidic acid (LPA) by conversion of lysophosphatidylcholine (LPC), present in human serum or plasma, and (ii) cyclic phosphatidic acid (cPA), an LPA analogue with distinct physiological activities. ATX activity accounts for the majority of LPA production in blood (Nakanaga et al., 2010) . The biological activity of LPA is largely mediated through the activation of five receptors, LPA1 to LPA5. All of these are type I, rhodopsin-like G protein-coupled receptors with seven-transmembrane alpha helices (Lin et al., 2010) . LPA evokes a wide variety of cellular responses in different cell types including Ras-mediated cell proliferation and Rho/Racregulated cell migration (including vascular endothelial cells migration), neurite retraction, platelet aggregation, smooth muscle contraction, actin stress fibers formation and cytokine/chemokine secretion. LPA levels are increased during pathological conditions of the brain (neuropsychiatric disorders such as bipolar disorders, schizophrenia, etc.). Deregulation of LPA signalling is found in cardiovascular diseases: the formation of excess fibrous connective tissues is strongly influenced by receptor-mediated LPA signalling in different organs (for example, lung, kidney and liver) (Lin et al., 2010) . Moreover, in both in vivo and in vitro systems, LPA has been shown to participate in critical events of cancer progression such as cell proliferation, growth, survival, migration, invasion, and promotion of angiogenesis (van Meeteren et al., 2007) . Therefore, LPA signalling is worth considering for its involvement in disease processes as well as in normal physiological functions. Autotaxin was originally identified as a tumour cell motility factor released in the spent medium of human melanoma cells. When overexpressed in Ras-NIH3T3 cells, ATX promotes tumour aggressiveness, metastasis and angiogenesis in nude mice (Nam et al., 2000) . ATX is highly expressed in several human cancers, including glioblastoma, lung and breast cancer, renal cell carcinoma, neuroblastoma, thyroid carcinoma and Hodgkin's lymphoma (Mills et al., 2003) . High ATX expression is detected in glioblastoma multiforme, a lethal cancer with a high infiltration rate (Hoelzinger et al., 2005) . ATX has also been found upregulated in stromal cells from prostate carcinoma patients (Zhao et al., 2007) and its expression is strongly enhanced by v-Jun oncogene-induced transformation (Black et al., 2004) and by overexpression of cancer-associated 6 4 integrin in breast cancer . In an in vivo angiogenesis model, ATX-transfected Ras-transformed NIH3T3 cells caused more prominent new blood vessel formation than control cells (Nam et al., 2000) . In addition, ATX stimulates human vascular endothelial cells grown on Matrigel to form tubules, similarly to the effects induced by vascular endothelial growth factor (VEGF) (Nam et al., 2001) . Recent studies have demonstrated the molecular mechanisms underlying the ATX/LPA axis in cancer. ATX-induced motility of melanoma cells is mediated through the activation of focal adhesion kinase (FAK) (Jung et al., 2004) and, in the nucleus, by the DNA binding of necrosis factor kappa B (NF-kB) (Lee et al., 2006) . Another finding is that LPA strongly counteracts Taxol-induced death in the MCF-7 breast cancer cell line and in MDA-MB-435 melanoma cells, by activating phosphatidylinositol 3-kinase (PI3K), which antagonizes the Taxol-induced accumulation of cancer cells in the G2/M phase of the cell cycle (Samadi et al., 2009) . Recently it has been demonstrated that the ATX/LPA axis allows breast cancer cells to escape from mitotic arrest following the PI3K-dependent displacement of Taxol from polymerised tubulin (Samadi et al., 2011) . Moreover, recent data from in vivo experiments indicate that increased expression of ATX, LPA1, LPA2 or LPA3 receptors in mice is associated with enhanced invasiveness of estrogen receptor-positive, metastatic breast cancers (Liu et al., 2009) . Finally, the significance of the plasma or serum ATX levels in cancer patients has been reported in patients with follicular lymphoma, where serum ATX levels proved to be significantly higher than those in healthy subjects, to correlate with plasma LPA levels and to change according to patient clinical course (Masuda et al., 2008) . Additional studies have reported an impressive and specific increase in serum ATX activity and plasma LPA in patients with chronic hepatitis C (Watanabe et al., 2007) and pancreatic cancer (Nakai et al., 2011) . In the last 20 years several studies have considered the potential role of the ATX/LPA axis in ovarian cancer. The high metastatic potential of ovarian carcinoma was suggested to be related to increased local production of LPA in the peritoneal cavity (Mills & Moolenaar, 2003) . Levels of LPA are markedly elevated in the ascites of patients with EOC (Mills et al., 1988) and in the plasma of 90% of stage I ovarian cancer patients, compared with healthy women (Xu et al., 1998) . The outcomes of LPA-driven signalling are determined by the expression level of LPA receptors on the cell surfaces. Indeed, normal ovarian epithelial cells express low levels of mRNA for LPA2 and LPA3, whereas the mRNA levels for LPA2 and particularly LPA3, are elevated in EOC (Fang et al., 2002) , suggesting a shift on ovarian cancer cells towards an LPA-dependent phenotype. Moreover >90% of LPA degradation by ovarian cancer cells is caused by the action of lipid phosphate phosphohydrolase-like (LPP-like) enzymes, whose expression differs between normal ovarian epithelium and epithelial ovarian cancer (Imai et al., 2000) . This implies that LPA, its receptors and downstream metabolic cascade might be potential targets for the design of novel ovarian cancer therapies. LPA has been found to induce VEGF expression (Hu et al., 2001 ) which in turn contributes to malignant ascites formation by increasing peritoneal microvessel permeability (Nagy et al., 1995) . A feedback model between ATX, LPA and VEGF in ovarian cancer cells has been recently proposed (Ptaszynska et al., 2008) . VEGF activates ATX transcription and subsequent protein secretion through VEGFR2. Increased secretion of ATX leads to an increased level of extracellular LPA. Completing the loop, LPA can stimulate VEGF and VEGFR2 expression through LPA receptor signalling thus enhancing tumour survival and growth. These data indicate that cross-talk between ATX and VEGF may be an important autocrine mechanism in the generation of an aggressive ovarian cancer phenotype. In addition, soluble ATX may be a beneficial target for cancer therapy because of its capacity to control both LPA production and signalling, and VEGF signalling. The development of drug resistance to cytotoxic therapies such as carboplatin and paclitaxel as well as to newly emerging therapies (Agarwal et al., 2003) , remains a high risk factor for ovarian cancer patients. Therefore, the identification of genes which confer drug resistance may offer novel therapeutic targets that can be exploited to develop drugs which re-sensitize tumour cells to chemotherapeutic agents (Richardson et al., 2005) . ATX has been linked to chemoresistance due to its ability to inhibit apoptosis induced by paclitaxel in breast cancer cells (Samadi et al., 2009) and LPA can inhibit cell death induced by cisplatin (Frankel et al., 1996) . It has been demonstrated that ATX may be a target for treating drug-resistant ovarian www.intechopen.com Ectoenzymes in Epithelial Ovarian Carcinoma: Potential Diagnostic Markers and Therapeutic Targets   257 cancer. The ectopic expression of ATX leads to the activation of a PI3K/Akt-mediated survival pathway, suggesting that ATX can delay carboplatin-induced cell death through the generation of LPA and the subsequent activation of the PI3K/Akt pathway (Vidot et al., 2010) . The inhibition of ATX in therapy has the advantage of providing a single extracellular drug target capable of blocking production of LPA. It has been observed that the primary effect of ATX is to delay apoptosis induced by carboplatin; since the exposure of tumour cells to carboplatin in patients is transient, accelerating the induction of apoptosis might be beneficial and may lead to improved tumour cell destruction. 
Conclusion
Improved understanding of the underlying biology of ovarian tumour progression and chemoresistance has led to the development of molecular targeted therapies. Ectoenzymes are attractive targets for designing new strategies to interfere with ovarian cancer progression and recurrence. This can be achieved by inhibiting the ectoenzymes that promote tumour migration and invasiveness (such as CD157 and CD13) or by inducing the activity of ectoenzymes that normally counteract tumour progression (such as CD26). In many cases, ectoenzymes can be inactivated either by specific monoclonal antibodies that block their function, or by small-molecule enzyme inhibitors. The dual nature of ectoenzymes warrants more detailed and vigorous investigation, because some of their functions seem to be independent of their enzymatic activities. It is conceivable that the large extracellular domains of ectoenzymes and their lateral interaction with other membrane proteins can mediate responses without involvement of their catalytic activity. However, many of the non-substrate ligands of ectoenzymes remain to be identified. Moreover, increasing evidence indicates that a number of ectoenzymes orchestrate the immune mechanisms underlying tumour progression and outcome and it is now evident that ovarian cancer features a number of different tumour evasion mechanisms. The future challenge will be to use a combinatorial approach to increase the existing anti-tumour response, dampen tumour evasion mechanisms and target crucial environmental players. 
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